Fridays vs Willow: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent researchHow we rank →

Fridays beats Willow overall, scoring 8.7/10 vs 8.2/10. Fridays is more affordable at $249/mo vs $299/mo. Choose Fridays for users who want a holistic program with coaching, nutrition s. Choose Willow for users who want comprehensive clinical support with flexibili.

A side-by-side comparison of Fridays and Willow covering pricing, scores, medication types, insurance, and more to help you decide.

Higher Rated

Fridays

#3 of 48
8.7/10

Holistic weight loss program combining GLP-1 medications with lifestyle coaching, nutrition guidance, and ongoing support.

Visit Fridays

Willow

#8 of 48
8.2/10

Personalized GLP-1 weight loss with ongoing clinical support. Compounded semaglutide and tirzepatide only — Willow explicitly does not prescribe brand-name Wegovy or Zepbound. Added oral compounded semaglutide tablets as a non-injectable option.

Visit Willow
FeatureFridaysWillow
Our Score8.7/108.2/10
Starting Price$249/mo$299/mo
Medication TypeBothCompounded
Insurance AcceptedYesNo
Best ForUsers who want a holistic program with coaching, nutrition support, and flexible pricingUsers who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes
Ranking#3#8

Pros & Cons Compared

Fridays

Pros

  • +One of the few platforms that bills insurance directly — can reduce out-of-pocket to $25-50/mo with coverage
  • +Includes 1-on-1 nutrition coaching and weekly check-ins, not just medication prescriptions
  • +Offers brand-name Wegovy/Zepbound and compounded options — switches based on insurance formulary
  • +Flexible plans: medication-only ($249/mo) or full coaching program ($299/mo)

Cons

  • The coaching-heavy model adds complexity — three different plan tiers with different inclusions
  • Without insurance, $249/mo for medication-only is above average for what you get clinically

Willow

Pros

  • +Includes monthly provider check-ins and dose adjustments at no extra cost
  • +Offers both injectable AND oral compounded semaglutide — one of few platforms with a daily oral tablet option
  • +$299/mo all-in for compounded semaglutide with monthly provider support
  • +90%+ patient retention rate after 3 months per their published outcomes data

Cons

  • Compounded-only — no brand-name Wegovy or Zepbound through the platform
  • Tirzepatide pricing reaches $499-$524 at higher doses — starting dose is $399/mo
  • Cash-pay only — no insurance billing, though they provide superbills for FSA/HSA
  • Founded in 2024 — less track record than Ro or Hims, though growth has been fast

Our Verdict

Fridays edges out Willow with a score of 8.7/10 vs 8.2/10. If budget is your priority, Fridays starts at $249/mo compared to Willow's $299/mo. Fridays accepts insurance, which can significantly reduce your out-of-pocket costs. Fridays offers both brand-name and compounded medications, giving you more flexibility. Choose Fridays if you want: users who want a holistic program with coaching, nutrition support, and flexible pricing. Choose Willow if you want: users who want comprehensive clinical support with flexibility between injectable and oral compounded semaglutide routes.

Still undecided? Editor's #1 Overall Pick

Eden Health GLP-1

$249/mo · 8.9/10 · Both

If neither Fridays nor Willow feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Eden Health GLP-1 — strongest balance of clinical oversight, transparent pricing, and verified availability.

Try Fridays

Starting at $249/mo

Visit Fridays

Try Willow

Starting at $299/mo

Visit Willow

Related comparisons

Other matchups readers comparing Fridays or Willow tend to look at next.

Top Picks

Four programs our readers click through most.

Eden Health GLP-1

8.9/10
$249/mo·Brand & Compounded

Embody

7.3/10
$299/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

Affiliate links — we earn a commission at no extra cost to you. Selection reflects what readers convert through, not editorial endorsement. Full ranking + methodology at glp1picks.com.